Transcription factor-based somatic cell reprogramming
=====================================================

In 2006, Takahashi and Yamanaka \[[@B1]\] demonstrated that differentiated cells can be converted into induced pluripotent stem cells (iPSCs) by the expression of four transcription factors - Oct4, Sox2, Klf4 and c-Myc - which have been termed Yamanaka factors. From the perspective of basic cell biology, somatic cell reprogramming has radically altered our thinking on the plasticity of cell states. In addition, the derivation of iPSCs from numerous normal and diseased cell sources has enabled the generation of patient-specific stem cells for eventual use in cell therapy and regenerative medicine. A number of alternatives and refinements to the original four-factor reprogramming method have been devised over the years. These have included ectopic expression of alternative reprogramming factors, such as Nanog and Lin28, manipulation of pathways that act as barriers to reprogramming, such as p53 and p21, transient expression of reprogramming proteins to avoid stable genetic modification, and inclusion of chemical inhibitors that increase the efficiency of the reprogramming process \[[@B2]\]. However, reprogramming largely remains dependent on the delivery and exogenous expression of one or more of the original Yamanaka factors.

The newly emerging role of miRNAs in reprogramming
==================================================

In a recent issue of *Cell Stem Cell*, Morrisey and colleagues \[[@B3]\] report that iPSCs can be generated solely through the expression of a set of miRNAs, thereby avoiding all original Yamanaka factors for the first time. This breakthrough is destined to expand our understanding of the pathways that drive reprogramming. Using lentivirus-based expression of the miR-302/367 cluster to reprogram both mouse and human cells, Morrisey and colleagues \[[@B3]\] show that miRNA-based reprogramming proceeds faster than with standard four-factor reprogramming. Consistent with this finding, pluripotency genes such as *Sox2*, *Nanog*and *Rex1*are upregulated earlier in fibroblasts expressing the miR-302/367 cluster than in fibroblasts transduced with the four transcription factors. Using a mouse line expressing a reporter gene with the *Oct4*promoter driving green fluorescent protein, the authors \[[@B3]\] also show that the endogenous *Oct4*locus is reactivated to a greater extent following miRNA expression than without miRNA expression. This rapid induction of endogenous pluripotency genes in the majority of target cells results in a significantly more efficient reprogramming process, up to two orders of magnitude higher than standard four-factor reprogramming. The authors \[[@B3]\] report that the miRNA-based approach can reprogram up to 10% of the input cells, although this could be an overestimation as only morphological criteria, and not pluripotency marker expression, were used to quantify the efficiency of reprogramming of human fibroblasts.

Several miRNA families are expressed exclusively and at high levels in embryonic stem cells (ESCs) \[[@B4]\]. ESC-specific miRNAs, such as the miR-290 and miR-302 families, are directly regulated by the pluripotency factors Oct4, Sox2 and Nanog and are thus integrated into the core pluripotency network \[[@B5]\]. These miRNA families have important roles in ESC self-renewal and pluripotency, as knocking out either of the two key enzymes in miRNA biogenesis (Dicer and DGCR8) leads to defects in ESC proliferation and differentiation \[[@B6]\]. Inhibition of Dicer and DGCR8 also decreases reprogramming efficiency, indicating that miRNA biogenesis is essential to robust reprogramming \[[@B7]\].

The miR-302/367 cluster used by Morrisey and colleagues \[[@B3]\] is composed of five miRNAs, four of which (miR-302a-d) have the same seed sequence - a seven base pair stretch of nucleotides that determines target specificity. The miR-302 family belongs to a subset of miRNAs referred to as ESC-specific cell-cycle-regulating (ESCC) miRNAs that regulate the G1-S transition and can rescue the cell cycle defect of DGCR8-null ESCs \[[@B8]\]. Another set of ESC-specific miRNAs, the miR-290 family, has been shown to substitute for c-Myc expression during reprogramming \[[@B9]\]. Recent work has revealed that the miR-302 and miR-290 family members both target many genes in several pathways, such as cell cycle regulation (*Cdk1na*, *Rbl2*) and epithelial-mesenchymal transitions (*RhoC*and *Tgfbr2*) \[[@B9]\]. Many of these target genes are functionally important, as inhibiting them individually using siRNAs or chemical inhibitors can also enhance four-factor reprogramming \[[@B9]\]. The seed sequence of the other miRNAs used in the new report \[[@B3]\], miR-367, is different from that of the miR-302 family. Importantly, exclusion of miR-367 from the miRNA cocktail abrogated reprogramming. In fact, without miR-367, endogenous Oct4 is never activated, suggesting that this miRNA either directly or indirectly regulates Oct4 expression. Given the wide variety of cellular processes targeted by these miRNAs, it is likely that simultaneous suppression of multiple targets is key to their reprogramming ability (Figure [1](#F1){ref-type="fig"}).

![**miRNA-mediated reprogramming. miRNAs achieve reprogramming potentially by repressing the repressors of pluripotency genes**. Genes involved in cell cycle progression, epithelial-mesenchymal transition (EMT) and epigenetic regulation are among genes that are targeted by the miR-302/367 cluster, but there are probably multiple important targets yet to be determined. Inhibition of HDAC2 by VPA, in conjunction with the miRNAs, is likely to enable reprogramming by promoting the activation of pluripotency genes.](gm256-1){#F1}

Potential mechanisms of miRNA-based reprogramming
=================================================

Although miRNA-based reprogramming did not require expression of any Yamanaka factors, reprogramming of mouse cells with the miRNAs did require the use of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor. Interestingly, VPA and other HDAC inhibitors have previously been shown to enhance four-factor reprogramming \[[@B10]\]. Using fibroblasts derived from *HDAC2*null mice, the authors \[[@B3]\] demonstrate that the effects of VPA are entirely dependent on the presence of this protein. Moreover, human fibroblasts express lower levels of HDAC2 than mouse fibroblasts, which may explain why miRNA-based reprogramming of human cells does not require VPA.

As in all standard retro- and lentiviral-based reprogramming methods, exogenous lentiviral miRNA expression is eventually silenced in the resulting iPSCs, when the endogenous pluripotency genes become reactivated. Because miRNAs primarily act as repressors of gene expression through mRNA degradation or inhibition of translation, it will be interesting to know how the endogenous pluripotency factors become activated during this process. In differentiated somatic cells these factors are kept silent by a combination of DNA and histone methylations; therefore, the miRNAs must somehow prompt the removal of these repressive chromatin marks \[[@B2]\]. A plausible scenario might be one in which the miRNAs target the enzymes that maintain these epigenetic marks. Inhibition of HDACs, which seem to be essential for miRNA-based reprogramming, at least in mice, may then shift the balance towards histone acetylation and transcriptional activation. Even then, how reprogramming is initiated in the absence of any strong transcriptional activator remains unresolved.

The future of miRNA-based reprogramming
=======================================

Apart from the fascinating biological questions raised by this report \[[@B3]\], miRNA-based reprogramming has important practical implications. Alternative methods of miRNA delivery, such as transfections of miRNA mimics, are worth pursuing as a way to generate iPSCs with no genomic integrations. Although there are non-integrating methods of delivering the Yamanaka factors, the low efficiency of these approaches has hampered their wide adoption. As miRNA-based reprogramming seems robustly efficient, even non-integrating methods such as miRNA transfection may generate appreciable numbers of iPSC clones. If rapid and efficient reprogramming by transient miRNA delivery becomes a reality, routine iPS derivation for future clinical applications may rely entirely on this method.
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